Document is current

Article History

Received: 18 January 2021

Revised: 28 March 2021

Accepted: 30 April 2021

First Online: 21 May 2021

Conflict of interest

: N.P.: honoraria: Amgen, Celgene, Janssen, Takeda, The Binding Site; consulting or advisory role: Amgen, Celgene, Janssen, Takeda; speakers’ bureau: Celgene; research funding: Celgene, Janssen, Amgen, Takeda; travel, accommodations, expenses: Amgen, Celgene, Janssen, Takeda. M.T.H.: consulting or advisory role: Celgene, Janssen, Amgen, Takeda, GSK; speakers’ bureau: Janssen, Celgene, Amgen. L.R.: honoraria from Janssen, Celgene, Amgen and Takeda. E.G.: no COIs to disclose. F.d.A.: honoraria from Janssen, Celgene, Amgen, GlaxoSmithKline and Takeda. A.O.: consultancy and speakers bureau for Celgene and Amgen, consultancy for Janssen, Sanofi, GSK. V.G.-C.: honoraria from Janssen and Celgene; research funding from Janssen (BECA SEHH-JANSSEN ESTANCIAS DE FORMACIÓN EN EL EXTRANJERO 2016–2017); consulting or advisory role for Prothena and Janssen. F.E.: no COIs to disclose. J.d.l.R. has served as a consultant and provided expert testimony within the past 2 years for Amgen, Celgene, Takeda, Janssen, and Sanofi. M.G.: honoraria for Janssen, Celgene, Takeda and Amgen. R.R.: consulting or advisory role for Janssen and Celgene; R.G.S.: Consulting or advisory role: BMS/Celgene, Janssen, Amgen, Takeda and GSK and speakers bureau from BMS/Celgene, Janssen, Amgen and GSK. J.M.A.: no COIs to disclose. A.A.: Consultancy and membership on an entity´s Board of Directors or advisory committees for Celgene-BMS, Amgen, Janssen, Sanofi, GSK and Takeda. J.M.: travel, accommodations and expenses from Amgen and Sandoz. N.C.G.: honoraria from Janssen-Cilag. M.J.C.: no COIs to disclose. M.L.M.: no COIs to disclose. M.d.C.C.: no COIs to disclose. M.C.: no COIs to disclose. M.A.: consultancy and honoraria for Janssen, Bristol-Myers Squibb, Celgene, Amgen and Takeda. E.P.P.: speakers bureau for Celgene/BMS, Amgen, Janssen, GSK. S.G.: consulting or advisory role for Janssen, Amgen, Takeda and Celgene. M.S.G.: no COIs to disclose. G.M.S.: no COIs to disclose. E.M.O.: Research funding: Array Pharmaceuticals, Mundipharma, Sanofi; consultancy, honoraria and research funding: Celgene, Amgen; consultancy and honoraria: Novartis, Takeda, Janssen; honoraria: B.M.S.; consultancy: AbbVie, Pharmamar, Seattle Genetics. M.C.: no COIs to disclose, C.E.: no COIs to disclose. A.M.V.: no COIs to disclose. A.I.T.: no COIs to disclose. M.C.R.: no COIs to disclose. B.P.: consultancy, honoraria, research funding and speaker’s bureau for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Roche and Sanofi; unrestricted grants from Celgene, EngMab and Takeda; consultancy for Celgene, Janssen and Sanofi; M.T.C.: Honoraria from Janssen, Celgene, Abbvie. J.F.S.-M.: consultancy or advisory role for Abbvie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, MSD, Novartis, Roche, Sanofi, SecuraBio and Takeda. J.J.L.: consulting or advisory role for Celgene, Takeda, Amgen, Janssen and Sanofi; travel accommodations and expenses for Celgene. J.B.: honoraria for Janssen, Celgene, Takeda, Amgen and Oncopeptides. R.N.: no COIs to disclose. M.V.M.: honoraria and membership on an entity´s Board of Directors or advisory committees for Janssen, Celgene, Takeda and Amgen, Adaptive, GSK, Sanofi and Oncopeptides; honoraria from membership in Board of Directors or advisory committees for Abbvie, Roche, Pfizer, Regeneron and Seattle Genetics.